Brown, Kyle A.
Gould, Todd D. http://orcid.org/0000-0003-1511-7183
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH107615)
U.S. Department of Veterans Affairs (1I01BX004062, 1I01BX006018)
Article History
Received: 22 June 2023
Revised: 20 December 2023
Accepted: 21 December 2023
First Online: 4 January 2024
Competing interests
: TDG is listed as an inventor in patents and patent applications related to the pharmacology and use of a ketamine metabolite, (2 R,6 R)-hydroxynorketamine, in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. TDG has assigned his patent rights to the University of Maryland, Baltimore, but will share a percentage of any royalties that may be received by the University of Maryland, Baltimore. KAB declares no competing interests.